8-K: GoodRx Reports First Quarter 2025 Results: Adjusted EBITDA Margin Beats Guidance

GoodRx's Q1 2025 revenue was in-line with expectations, while adjusted EBITDA margin exceeded previous guidance, and the company maintained its full-year revenue guidance range while raising adjusted EBITDA expectations.

Summary

• GoodRx reported its financial results for the first quarter of 2025.
• Revenue increased by 3% to $203.0 million compared to $197.9 million in the same period last year.
• Net income was $11.1 million, a significant improvement from the net loss of $1.0 million in the prior year.
• Adjusted EBITDA was $69.8 million, up from $62.8 million year-over-year, with an adjusted EBITDA margin of 34.4%.
• The company exited the quarter with over 7 million consumers of prescription-related offerings.
• For the full year 2025, GoodRx anticipates revenue between $810 and $840 million, representing 2% to 6% growth compared to 2024.
• Adjusted EBITDA for the full year is expected to be between $273 and $287 million, representing approximately 5% to 10% growth compared to 2024.
• In Q1 2025, GoodRx repurchased 23.3 million shares of Class A common stock for $100.9 million.
• As of March 31, 2025, $189.4 million remained available under the $450.0 million share repurchase program.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the in-line revenue, improved net income, and raised adjusted EBITDA expectations. However, some concerns remain regarding subscription revenue decline and changes in operating cash flow.

Positives

• Revenue increased by 3% to $203.0 million.
• Net income improved significantly to $11.1 million.
• Adjusted EBITDA margin exceeded previous guidance at 34.4%.
• Pharma manufacturer solutions revenue increased 17% to $28.6 million.
• The company repurchased 23.3 million shares of Class A common stock for $100.9 million.
• GoodRx is focused on a disciplined approach to capital allocation, centered on furthering their mission and creating shareholder value.

Negatives

• Subscription revenue decreased 7% to $21.0 million, primarily due to the sunset of the Kroger Savings Club partnership.
• Net cash provided by operating activities decreased to $9.4 million compared to $42.6 million in the prior year.
• Prescription transactions revenue increased 2% to $148.9 million, partially offset by a 4% decrease in Monthly Active Consumers, primarily due to the broader changes in the retail pharmacy landscape.

Risks

• Macroeconomic conditions, such as consumer confidence and spending trends, could impact revenue.
• Tariffs and other policies related to drug pricing pose a risk to revenue.
• Economic climate and ongoing business development efforts can influence strategic initiatives.
• The company's ability to attract, acquire, and retain consumers in a cost-effective manner is crucial.
• Changes in medication pricing and the significant impact of pricing structures negotiated by industry participants could affect results.
• Reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers, presents a risk.

Future Outlook

For the full year 2025, GoodRx expects revenue to be in the range of $810 to $840 million, representing 2% to 6% growth compared to 2024, and adjusted EBITDA to be between $273 and $287 million, representing approximately 5% to 10% growth compared to 2024.

Management Comments

• Wendy Barnes, Chief Executive Officer and President of GoodRx, stated that the company is in a very strong position to deliver meaningful value across the pharmacy ecosystem and is focused on high-impact initiatives.
• Chris McGinnis, Chief Financial Officer and Treasurer, noted that the company continues to believe that revenue will be in the range of $810 to $840 million for the full year 2025.
• Chris McGinnis also stated that for the second quarter, they expect revenue to be up sequentially from the $203 million reported in the first quarter with an Adjusted EBITDA Margin roughly similar to the first quarter.

Industry Context

GoodRx operates in the competitive landscape of prescription savings platforms, facing competition from companies like SingleCare, Optum Perks (formerly ScriptSave WellRx), and others. The company's focus on expanding its pharma manufacturer solutions and maintaining a strong position in prescription transactions is crucial for sustaining growth in this environment.

Comparison to Industry Standards

• Comparing GoodRx's adjusted EBITDA margin of 34.4% to other players in the healthcare technology space, such as Teladoc Health or Amwell, shows a relatively strong profitability metric.
• However, these companies operate in different segments, making direct comparisons challenging.
• For example, Teladoc Health, while focused on telehealth, has different revenue models and cost structures.
• Similarly, comparing GoodRx's revenue growth to that of other digital health companies like One Medical (now part of Amazon) reveals varying growth trajectories based on specific market focuses and business strategies.
• GoodRx's focus on prescription savings provides a unique niche compared to broader healthcare service providers.

Stakeholder Impact

• Shareholders will likely react positively to the improved profitability and share repurchase program.
• Consumers will continue to benefit from medication savings through the GoodRx platform.
• Partners, including pharmacies and pharma manufacturers, will see continued collaboration opportunities.
• Employees may experience stability due to the company's focus on profitable growth.

Next Steps

• GoodRx management will host a conference call and webcast on May 8, 2025, to discuss the results and the Company's business outlook.
• The company intends to continue investing for profitable growth, paying down debt, buying back shares, and pursuing M&A opportunities.

Key Dates

Keywords

GoodRx, financial results, Q1 2025, revenue, EBITDA, prescription, pharmacy, healthcare, guidance, stock repurchase